Market Cap : 16.05 B | Enterprise Value : 13.37 B | PE Ratio : 16.98 | PB Ratio : 3.92 |
---|
NAS:INCY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:INCY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Incyte's current ratio for the quarter that ended in Jun. 2022 was 3.91.
Incyte has a current ratio of 3.91. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Incyte's Current Ratio or its related term are showing as below:
During the past 13 years, Incyte's highest Current Ratio was 21.14. The lowest was 1.51. And the median was 4.05.
INCY's Current Ratio is ranked worse thanThe historical data trend for Incyte's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Incyte's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Incyte's Current Ratio distribution charts can be found below:
* The bar in red indicates where Incyte's Current Ratio falls into.
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
Incyte's Current Ratio for the fiscal year that ended in Dec. 2021
Incyte's Current Ratio for the quarter that ended in Jun. 2022 is calculated as * For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
Current Ratio (A: Dec. 2021 ) = Total Current Assets (A: Dec. 2021 ) / Total Current Liabilities (A: Dec. 2021 )
= 3118.674 / 854.308
= 3.65
Current Ratio (Q: Jun. 2022 ) = Total Current Assets (Q: Jun. 2022 ) / Total Current Liabilities (Q: Jun. 2022 )
= 3625.845 / 926.674
= 3.91
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Thank you for viewing the detailed overview of Incyte's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Tray Thomas | officer: Principal Accounting Officer | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Brawley Otis W | director | 5203 BRISTOL INDUSTRIAL WAY BUFORD GA 30518 |
High Katherine A | director | 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104 |
Harrigan Edmund | director | |
Morrissey Michael James | officer: EVP, Head of Tech. Operations | IN CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803 |
Dickinson Jonathan Elliott | officer: EVP, General Manager, Europe | CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803 |
Stamoulis Christiana | officer: EVP & Chief Financial Officer | C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139 |
Dhanak Dashyant | officer: EVP & Chief Scientific Officer | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Pasquale Maria E | officer: EVP & General Counsel | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Fouse Jacqualyn A | director | C/O DICK'S SPORTING GOODS 345 COURT STREET CORAOPOLIS PA 15108 |
Iyengar Vijay K | officer: EVP GPS, BD, & Licensing | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Stein Steven H | officer: EVP & Chief Medical Officer | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Trower Paul | officer: VP, Finance & Prin Acc Officer | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Clancy Paul J | director | C/O BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 |
Bienaime Jean Jacques | director | 925 PAGE MILL ROAD PALO ALTO CA 94304 |
From GuruFocus
Other Sources
By Seekingalpha 2021-11-02
By Zacks 2022-01-27
By Seekingalpha 2022-01-24
By tipranks.com 2022-03-27
By Zacks 2022-03-28
By Seekingalpha 2021-12-28
By tipranks.com 2022-02-08
By Zacks 2022-02-09
By tipranks.com 2022-02-11
By Zacks 2021-12-16
By tipranks.com 2022-02-09
By Zacks 2022-02-08
By Zacks 2022-01-31
By tipranks.com 2022-03-14